TY - JOUR
T1 - Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment
AU - Herukka, Sanna Kaisa
AU - Simonsen, Anja Hviid
AU - Andreasen, Niels
AU - Baldeiras, Ines
AU - Bjerke, Maria
AU - Blennow, Kaj
AU - Engelborghs, Sebastiaan
AU - Frisoni, Giovanni B.
AU - Gabryelewicz, Tomasz
AU - Galluzzi, Samantha
AU - Handels, Ron
AU - Kramberger, Milica G.
AU - Kulczyńska, Agnieszka
AU - Molinuevo, Jose Luis
AU - Mroczko, Barbara
AU - Nordberg, Agneta
AU - Oliveira, Catarina Resende
AU - Otto, Markus
AU - Rinne, Juha O.
AU - Rot, Uroš
AU - Saka, Esen
AU - Soininen, Hilkka
AU - Struyfs, Hanne
AU - Suardi, Silvia
AU - Visser, Pieter Jelle
AU - Winblad, Bengt
AU - Zetterberg, Henrik
AU - Waldemar, Gunhild
PY - 2017/3/1
Y1 - 2017/3/1
N2 - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1–42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.
AB - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1–42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.
KW - Alzheimer's disease
KW - Biomarkers
KW - CSF
KW - Diagnostics
KW - GRADE
KW - Mild cognitive impairment
KW - Recommendations
UR - http://www.scopus.com/inward/record.url?scp=85007323510&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jalz.2016.09.009
DO - https://doi.org/10.1016/j.jalz.2016.09.009
M3 - Short survey
C2 - 28341066
SN - 1552-5260
VL - 13
SP - 285
EP - 295
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 3
ER -